Ang-(1-7) for Hypesthesia

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Banner - University Medical Center, Phoenix, AZ
Hypesthesia+3 More
Angiotensin 1-7 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing whether a drug called Ang-(1-7) can prevent cognitive impairment in people with heart failure who are at risk for developing VCID/ADRD. The trial will last for one year, and participants will have to undergo neuropsychological testing and blood draws at baseline and at the 12-month mark. They will also be given weekly check-ins during the 12-week treatment period. Ang-(1-7) is used to treat hypesthesia, which can be done online. The treatment is free.

Eligible Conditions

  • Hypesthesia

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Hypesthesia

Study Objectives

36 Primary · 0 Secondary · Reporting Duration: These measurements will be taken at the 12 month follow up

Week 12
12-week Blood Biomarkers - Neurology 4-Pleax A, pTau-181, and pTau 231 as measured by the Quanterix Simoa Neurology 4-plex A and Simoa pTau-181 and 283 advantage kits
12-week evaluations of associative, verbal memory as measured by the verbal paired associates task (version 2)
12-week evaluations of associative, visual memory as measured by the Face Name Associative Memory Test
12-week evaluations of executive functions - attention/inhibition as measured by the Flanker Task
12-week evaluations of executive functions - switching as measured by the Number-Letter Task
12-week evaluations of executive functions - updating/working memory as measured by the Keep Track Task
12-week evaluations of global cognitive functioning as measured by the Montreal Cognitive Assessment
12-week evaluations of pattern separation memory as measured by the Mnemonic Similarity Task
12-week evaluations of processing speeds - simple/complex processing speeds as measured by the Deary-Liewald Reaction Time Task
12-week evaluations of reading ability/vocabulary as measured by the North American Reading Test
These measurements will be taken at baseline
Baseline Blood Biomarkers - Neurology 4-Pleax A, pTau-181, and pTau 231 as measured by the Quanterix Simoa Neurology 4-plex A and Simoa pTau-181 and 283 advantage kits
Baseline evaluations of associative, verbal memory as measured by the verbal paired associates task (version 2)
Baseline evaluations of associative, visual memory as measured by the Face Name Associative Memory Test
Baseline evaluations of executive functions - attention/inhibition as measured by the Flanker Task
Baseline evaluations of executive functions - switching as measured by the Number-Letter Task
Baseline evaluations of executive functions - updating/working memory as measured by the Keep Track Task
Baseline evaluations of global cognitive functioning as measured by the Montreal Cognitive Assessment
Baseline evaluations of pattern separation memory as measured by the Mnemonic Similarity Task
Baseline evaluations of processing speeds - simple/complex processing speeds as measured by the Deary-Liewald Reaction Time Task
Baseline evaluations of reading ability/vocabulary as measured by the North American Reading Test
Month 12
12-month Blood Biomarkers - Neurology 4-Pleax A, pTau-181, and pTau 231 as measured by the Quanterix Simoa Neurology 4-plex A and Simoa pTau-181 and 283 advantage kits
12-month evaluations of associative, verbal memory as measured by the verbal paired associates task (version 2)
12-month evaluations of associative, visual memory as measured by the Face Name Associative Memory Test
12-month evaluations of executive functions - attention/inhibition as measured by the Flanker Task
12-month evaluations of executive functions - switching as measured by the Number-Letter Task
12-month evaluations of executive functions - updating/working memory as measured by the Keep Track Task
12-month evaluations of global cognitive functioning as measured by the Montreal Cognitive Assessment
12-month evaluations of pattern separation memory as measured by the Mnemonic Similarity Task
12-month evaluations of processing speeds - simple/complex processing speeds as measured by the Deary-Liewald Reaction Time Task
12-month evaluations of reading ability/vocabulary as measured by the North American Reading Test
Participants disability due to health/mental health conditions will be assessed as measured by the World Health Organization Disability Assessment Schedule 2.0
Participants heart failure health status will be assessed as measured by the Kansas City Cardiomyopathy Questionnaire
Participants independent living skills will be assessed as measured by the Lawton-Brody Instrumental Activities of Daily Living Scale (I.A.D.L)
Participants physical activity will be assessed as measured by Rapid Assessment of Physical Activity
Participants quality of life will be assessed as measured by the World Health Organization Quality of Life - BREF (WHOQOL-BREF)
Participants sleep quality will be assessed as measured by the Pittsburgh Sleep Quality Index

Trial Safety

Safety Progress

1 of 3

Other trials for Hypesthesia

Trial Design

2 Treatment Groups

Ang-(1-7)
1 of 2
Saline Placebo
1 of 2
Experimental Treatment
Non-Treatment Group

40 Total Participants · 2 Treatment Groups

Primary Treatment: Ang-(1-7) · Has Placebo Group · Phase 1 & 2

Ang-(1-7)
Drug
Experimental Group · 1 Intervention: Angiotensin 1-7 · Intervention Types: Drug
Saline Placebo
Drug
PlaceboComparator Group · 1 Intervention: Saline solution · Intervention Types: Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: these measurements will be taken at the 12 month follow up
Closest Location: Banner - University Medical Center · Phoenix, AZ
Photo of Phoenix 1Photo of Phoenix 2Photo of Phoenix 3
N/AFirst Recorded Clinical Trial
0 TrialsResearching Hypesthesia
0 CompletedClinical Trials

Who is running the clinical trial?

University of ArizonaLead Sponsor
447 Previous Clinical Trials
153,941 Total Patients Enrolled
Lee Ryan, Ph.D.Principal InvestigatorUniversity of Arizona

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are a fluent English speaker.
You have HF with symptoms during exercise but not at rest.
You are on a stable medical regimen and free from hospitalizations in the prior 30 days.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.